CTLA4 and non-small cell lung carcinoma: A retrospective review by Hendriks et al. analyzed 19 patients with LMD from non-small cell lung cancer (NSCLC) treated with intravenous (IV) ICIs, including PDL-1 inhibitors with or without anti-CTLA4 antibodies [18].